Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer

Wan,Shuqiong; Zhao,Huanqiu

doi:10.3892/ol.2020.12044

Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer

Authors:
- Shuqiong Wan
- Huanqiu Zhao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Huangshi Central Hospital, Huangshi, Hubei 435000, P.R. China, Department of Gynecology, Huangshi Maternity and Children's Health Hospital, Huangshi, Hubei 435000, P.R. China
Published online on: August 31, 2020 https://doi.org/10.3892/ol.2020.12044
Article Number: 183

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the diagnostic and prognostic value of lncRNA maternally expressed 3 (MEG3) in cervical cancer. Eighty‑four patients with cervical cancer from February 2013 to March 2014 were enrolled in the observation group (OG), and another 58 female subjects who underwent physical examination at Huangshi Central Hospital were enrolled as the control group (CG). The serum MEG3 expression of patients in the two groups was detected by RT‑qPCR, and the ability of MEG3 to aid in the diagnosis of cervical cancer, lymph node metastasis and FIGO staging, as well as to predict mortality was evaluated by ROC curve. In addition, the patients in the OG were divided into high‑ and low‑expression groups according to the median value of MEG3. Kaplan Meier was employed to analyze the survival status, and Cox regression to analyze the independent prognostic factors of cervical cancer patients. The results of the present study revealed that the serum MEG3 expression in the OG was significantly lower than that of the CG (P<0.05). The area under the curve (AUC) of MEG3 in diagnosing cervical cancer was 0.844, the AUC in predicting mortality was 0.858, while that in diagnosing lymph node transfer was 0.707, and that in diagnosing FIGO staging was 0.791. The 5‑year survival rate of the high‑expression group was higher than that of the low‑expression group (P=0.020). Multivariate analysis indicated that MEG3 (HR, 0.173; 95 CI%, 0.028‑0.919), lymph node metastasis (HR, 2.259; 95 CI%, 1.004‑5.025) and FIGO staging (HR, 0.008; 95 CI%, 1.453‑6.248) were independent prognostic factors for cervical cancer patients. Collectively, lncRNA MEG3 may be a diagnostic marker and prognostic indicator for cervical cancer, and has a certain diagnostic value for lymph node metastasis and FIGO staging. Lymph node metastasis, FIGO stage III and IV, and low MEG3 levels were revealed to be independent prognostic factors for cervical cancer patients.

View Figures

View References

1	Guo L, Lu X, Zheng L, Liu X and Hu M: Association of long non-coding RNA HOTAIR polymorphisms with cervical cancer risk in a Chinese population. PLoS One. 11:e01600392016. View Article : Google Scholar : PubMed/NCBI
2	Hang D, Yin Y, Han J, Jiang J, Ma H, Xie S, Feng X, Zhang K, Hu Z, Shen H, et al: Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. Virology. 488:156–161. 2016. View Article : Google Scholar : PubMed/NCBI
3	Liang Y, Sun R, Li L, Yuan F, Liang W, Wang L, Nie X, Chen P, Zhang L and Gao L: A functional polymorphism in the promoter of MiR-143/145 is associated with the risk of cervical squamous cell carcinoma in Chinese women: A case-control study. Medicine (Baltimore). 94:e12892015. View Article : Google Scholar : PubMed/NCBI
4	Li H, Wu X and Cheng X: Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
5	Jing H, Qu X, Liu L and Xia H: A novel long noncoding RNA (lncRNA), LL22NC03-N64E9. 1, promotes the proliferation of lung cancer cells and is a potential prognostic molecular biomarker for lung cancer. Med Sci Monit. 24:43172018. View Article : Google Scholar : PubMed/NCBI
6	Xiao B, Huang Z, Zhou R, Zhang J and Yu B: The prognostic value of expression of the long noncoding RNA (lncRNA) small nucleolar RNA Host Gene 1 (SNHG1) in patients with solid malignant tumors: A systematic review and meta-analysis. Med Sci Monit. 24:5462–5472. 2018. View Article : Google Scholar : PubMed/NCBI
7	Hao S, Yao L, Huang J, He H, Yang F, Di Y, Jin C and Fu D: Genome-wide analysis identified a number of dysregulated long noncoding RNA (lncRNA) in human pancreatic ductal adenocarcinoma. Technol Cancer Res Treat. 17:15330346177484292018. View Article : Google Scholar : PubMed/NCBI
8	Fu XM, Guo W, Li N, Liu HZ, Liu J, Qiu SQ, Zhang Q, Wang LC, Li F and Li CL: The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur Rev Med Pharmacol Sci. 21:3239–3246. 2017.PubMed/NCBI
9	Misawa A, Takayama K, Urano T and Inoue S: Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate cancer cells. J Biol Chem. 291:17861–17880. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chen T, Xie W, Xie L, Sun Y, Zhang Y, Shen Z, Sha N, Xu H, Wu Z, Hu H and Wu C: Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer. Biochem Biophys Res Commun. 468:666–670. 2015. View Article : Google Scholar : PubMed/NCBI
11	He Y, Luo Y, Liang B, Ye L, Lu G and He W: Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 8:73282–73295. 2017. View Article : Google Scholar : PubMed/NCBI
12	Ghafouri-Fard S and Taheri M: Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. Biomed Pharmacother. 118:1091292019. View Article : Google Scholar : PubMed/NCBI
13	Sun KX, Wu DD, Chen S, Zhao Y and Zong ZH: lncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. Apoptosis. 22:1543–1552. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Xu W, He Y, Xia Q and Liu S: lncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflamm Res. 67:927–936. 2018. View Article : Google Scholar : PubMed/NCBI
15	Cui X, Jing X, Long C, Tian J and Zhu J: Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: A meta-analysis. Oncotarget. 8:19049–19056. 2017. View Article : Google Scholar : PubMed/NCBI
16	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Migdalska-Sęk M, Karowicz-Bilińska A, Pastuszak-Lewandoska D, Czarnecka KH, Nawrot E, Domańska-Senderowska D, Kiszałkiewicz J and Brzeziańska-Lasota E: Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: A pilot study. Med Oncol. 33:512016. View Article : Google Scholar : PubMed/NCBI
19	Peng L, Yuan X, Jiang B, Tang Z and Li GC: lncRNAs: Key players and novel insights into cervical cancer. Tumour Biol. 37:2779–2788. 2016. View Article : Google Scholar : PubMed/NCBI
20	González-Quintana V, Palma-Berré L, Campos-Parra AD, López-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo R and Pérez-Plasencia C: MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). Oncol Rep. 35:3–12. 2016. View Article : Google Scholar : PubMed/NCBI
21	Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V and Mangioni C: Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 28:e342017. View Article : Google Scholar : PubMed/NCBI
22	Kong TW, Piao X, Chang SJ, Paek J, Lee Y, Lee EJ and Ryu HS: A predictive model for parametrial invasion in patients with FIGO stage IB cervical cancer: Individualized approach for primary treatment. Int J Gynecol Cancer. 26:184–191. 2016. View Article : Google Scholar : PubMed/NCBI
23	Qin R, Chen Z, Ding Y, Hao J, Hu J and Guo F: Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma. 60:486–492. 2013. View Article : Google Scholar : PubMed/NCBI
24	Chen X and Qu J: Long non-coding RNA MEG3 suppresses survival, migration, and invasion of cervical cancer. Onco Targets Ther. 11:4999–5007. 2018. View Article : Google Scholar : PubMed/NCBI
25	Xiu YL, Sun KX, Chen X, Chen S, Zhao Y, Guo QG and Zong ZH: Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. Oncotarget. 8:31714–31725. 2017. View Article : Google Scholar : PubMed/NCBI
26	Zhang W, He W, Shi Y, Zhao J, Liu S, Zhang F, Yang J, Xie C and Zhang Y: Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma. Int J Oncol. 50:173–184. 2017. View Article : Google Scholar : PubMed/NCBI
27	Rofstad EK, Huang R, Galappathi K, Andersen LM, Wegner CS, Hauge A, Gaustad JV and Simonsen TG: Functional intratumoral lymphatics in patient-derived xenograft models of squamous cell carcinoma of the uterine cervix: Implications for lymph node metastasis. Oncotarget. 7:56986–56997. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhang J, Yao T, Wang Y, Yu J, Liu Y and Lin Z: Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 17:104–113. 2016. View Article : Google Scholar : PubMed/NCBI